Somatostatin analogs for cancer treatment and diagnosis: An overview

Chemotherapy

Volumn 47, Issue SUPPL. 2, 2001, Pages 1-29

  Scarpignato, Carmelo ^a,b,c   Pelosini, Iva ^a  

^a UNIVERSITY OF PARMA   (Italy)

^b UNIVERSITÉ DE NANTES   (France)

^c Maggiore University Hospital   (Italy)

Author keywords

Cancer treatment; Lanreotide; Octreotide; Somatostatin; Somatostatin receptor scintigraphy; Somatostatin receptor targeted radiotherapy; Vapreotide

Indexed keywords

ANGIOPEPTIN; HORMONE; OCTREOTIDE; SOMATOSTATIN 2 RECEPTOR; SOMATOSTATIN 5 RECEPTOR; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG; VAPREOTIDE;

ACROMEGALY; ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CYTOTOXICITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GENE THERAPY; HALF LIFE TIME; HUMAN; ISOTOPE LABELING; METASTASIS; NEUROENDOCRINE TUMOR; PALLIATIVE THERAPY; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; REVIEW; SCINTIGRAPHY;

EID: 0035078132     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000049157     Document Type: Review

References (153)

1. Principles of cancer management: Chemotherapy
2. Oncological applications of somatostatin analogs
3. The role of somatostatin and its analogs in the diagnosis and treatment of tumors
4. Antiproliferative somatostatin analogues with potential in oncology
5. Octreotide and nonendocrine tumors: Basic knowledge and therapeutic potential
6. Somatostatin and cancer
7. Somatostatin analogs: Angiogenesis inhibitors with novel mechanisms of action
8. The significance of somatostatin analogues in the antiproliferative treatment of carcinomas
9. Working Team Report: The effect of somatostatin on cellular proliferation
10. Mechanisms of antineoplastic action of somatostatin analogs
11. Antiproliferative effect of somatostatin analogs
12. Established clinical use of octreotide and lanreotide in oncology
13. Safety profile of octreotide
14. The role of octreotide scintigraphy in clinical diagnosis and therapy
15. Somatostatin receptor scintigraphy
16. Radiolabelled somatostatin analogue scintigraphy in oncology
17. Vasointestinal peptide and somatostatin receptor scintigraphy for diagnosis and treatment of tumor patients
18. Therapy of neurometastatic tumors with radiolabelled MIBG somatostatin analogues
19. 1]-octreotide
20. Somatostatin: The early days
21. Chemistry and pharmacology of SMS 201-995, a long-acting octapeptide analogue of somatostatin
22. Pharmacokinetics and effects of intravenous infusion of somatostatin in normal subjects - A two-compartment open model
23. Inactivation of somatostatin (GH-RIH) and its analogs by crude and partially purified rat brain extracts
24. Chemical structure - Pharmacological profile of Sandostatin®
25. Biologic and immunologic activities and applications of somatostatin analogs
26. Octreotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion
27. Octreotide
28. Octreotide, the synthetic long-acting somatostatin analogue: Pharmacological profile
29. The use of new somatostatin analogs, lanreotide and octastatin, in neuroendocrine gastrointestinal tumors
30. Effects of lanreotide, a somatostatin analogue, on postprandial gastric functions and biliopancreatic secretions in humans
31. Stabilization of Octastatin, a somatostatin analogue: Comparative accelerated stability studies of two formulations for freeze-dried products
32. A potent cyclic hexapeptide analogue of somatostatin
33. Cyclic hexapeptide analogs of somatostatin containing bridge modifications. Syntheses and conformational analyses
34. Disposition of Sandostatin, a new synthetic somatostatin analogue in rats
35. From somatostatin to Sandostatin®: Pharmacodynamics and pharmacokinetics
36. Clinical pharmacokinetics of octreotide. Therapeutic applications in patients with pituitary tumors
37. Chemical structure - Pharmacological profile of Sandostatin®
38. Distribution and metabolism of exogenous somatostatin in rats
39. Pharmacokinetics of SMS 201-995 in healthy subjects
40. Somatostatin and octreotide: Literature review and description of therapeutic activity in pancreatic neoplasia
41. The use of long-acting somatostatin analog octreotide in the treatment of gut neuroendocrine tumors
42. Pharmacokinetics of the long-acting somatostatin analogue octreotide (SMS 201-995) in acromegaly
43. A randomized comparison of intranasal and injectable octreotide administration in patients with acromegaly
44. Pharmacokinetics of SMS 201-995 in normal subjects and in patients with severe renal failure
45. Pharmacokinetic study effects on growth hormone secretion in healthy volunteers of the new somatostatin analogue BIM 23014
46. Pharmacokinetics of lanreotide
47. Lanreotide acetate
48. Somatostatin receptors
49. Somatostatin and its receptor family
50. Somatostatin receptors: Present knowledge and future directions
51. Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hSSTR 1-5)
52. The somatostatin receptor family
53. Octreotide and nonendocrine tumors: Basic knowledge and therapeutic potential
54. Somatostatin receptors and disease: Role of receptor subtypes
55. Clinical significance of tumor somatostatin receptor subtype expression
56. Somatostatin receptor subtype expression in human tissues: A prediction for diagnosis and treatment of cancer?
57. High density of somatostatin receptors in pituitary tumors from acromegalic patients
58. Plasma growth hormone responses to somatostatin (SRIH) and SRIH receptors in pituitary adenomas in acromegalic patients
59. Tumour angiogenesis: Therapeutic implications
60. What is the evidence that tumors are angiogenesis dependent?
61. Tumour angiogenesis: Pathophysiology and clinical significance
62. Expression of somatostatin receptors in peritumoral veins of human tumors
63. Stimulatory effects of insulin and insulin-like growth factor 1 on migration and tube formation by vascular endothelial cells
64. Induction of apoptosis by cancer chemotherapy
65. The insulin-like growth factor I receptor: A key to tumor growth?
66. Induction of apoptosis in neuroendocrine tumors of the digestive system during treatment with somatostatin analogs
67. Continuous subcutaneous pump infusion of somatostatin analogue SMS 201-995 versus subcutaneous injection schedule in acromegalic patients
68. The effect of subcutaneous infusion versus subcutaneous injections of a somatostatin analogue (SMS 201-995) on the diurnal GH profile in acromegaly
69. Long-term effects of continuous subcutaneous infusion of the somatostatin analog octreotide in the treatment of acromegaly
70. Octreotide treatment in acromegaly: A comparison between pen-treated and pump-treated patients in a cross-over study
71. Comparison of octreotide delivered by continuous subcutaneous infusion with intermittent injection in the treatment of acromegaly
72. Octreotide nasal power in acromegalic patients: A dose-range and tolerability study
73. Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly
74. Sandostatin LAR®: Pharmacokinetics, pharmacodynamics, efficacy and tolerability in acromegalic patients
75. Sandostatin LAR: Pharmacokinetics, tolerability and efficacy in 24 acromegalic patients
76. Sandostatin LAR in acromegalic patients: A dose range and tolerability study
77. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome
78. Pharmacokinetic and pharmacodynamic properties of a long-acting formulation of the new somatostatin analogue, lanreotide, in normal healthy volunteers
79. Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly
80. Slow-release lanreotide treatment in acromegalic patients previously normalized by octreotide
81. Long-term treatment of acromegaly with the slow-release somatostatin analogue lanreotide
82. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: Six-month report on an Italian multicentre study
83. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly
84. Long-term treatment of acromegaly with the somatostatin analogue SR-lanreotide
85. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: Six-month report on an Italian multi-center study
86. The place of octreotide in the medical management of neuroendocrine gut tumors
87. Treatment of the carcinoid syndrome with the long-acting somatostatin analogue lanreotide: A prospective study in 39 patients
88. The role of somatostatin analogues in the treatment of gastro-enteropancreatic endocrine tumors
89. Slow-release lanreotide treatment in endocrine gastrointestinal tumors
90. Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms
91. Long-acting formulations of somatostatin analogues
92. Radioimmunoassay for octapeptide analogs of somatostatin: Measurement of serum levels after administration of long-acting microcapsule formulations
93. Development and evaluation in vivo of a long-term delivery system for vapreotide, a somatostatin analogue
94. Tumour markers in neuroendocrine tumors
95. Advances in radio-imaging of neuroendocrine tumors
96. Localization of gastroenteropancreatic tumors by angiography
97. Somatostatin receptor subtypes, octreotide scintigraphy, and clinical response to octreotide treatment in patients with neuroendocrine tumors
98. Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours
99. A comparison between the efficacy of somatostatin receptor scintigraphy and that of in situ hybridization for somatostatin receptor subtype 2 messenger RNA to predict therapeutic outcome in carcinoid patients
100. 3]-octreotide
101. 1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: Synthesis, radiolabeling and in vivo validation
102. 111In-octreotide
103. Indium-111-DOTA-lanreotide: Biodistribution, safety and radiation absorbed dose in tumor patients
104. 1]octreotide
105. Tc-99m-RC-160: A somatostatin analog for imaging prostate cancer - Comparison with I-125-RC-160 and In-111-octreotide
106. 'MAURITIUS': Tumor dose in patients with advanced carcinoma
107. Single photon emission computed tomography procedure improves accuracy of somatostatin receptor scintigrapy in gastro-entero pancreatic tumors
108. Intraoperative gamma detection reveals abdominal endocrine tumors more efficiently than somatostatin receptor scintigraphy
109. Intra-operative gamma probe detection of neuroendocrine tumors
110. Intraoperative localization of gut endocrine tumors with radiolabeled somatostatin analogs and a gamma-detecting probe
111. Clinical applications of gamma-detection probes - Radioguided surgery
112. 161Tb-DTPA-octreotide, a somatostatin with potential for intraoperative scanning and radiotherapy
113. Gallium-67/gallium-68-[DFO]-octreotide - A potential radiopharmaceutical for PET imaging of somatostatin receptor-positive tumors: Synthesis and radiolabeling in vitro and preliminary in vivo studies
114. In vitro and in vivo evaluation of copper-64-octreotide conjugates
115. Radiotherapy, toxicity and dosimetry of copper-64-TETA-octreotide in tumor-bearing rats
116. PET-pharmacokinetics of (18)F-octreotide: A comparison with (67)Ga-DFO- and (86)Y-DTPA-octreotide
117. Positron emission tomography in neuroendocrine tumors
118. Radiolabelled peptides: Now and the future
119. Kinetics of internalization and recycling of the asialogly-coprotein receptor in a hepatoma cell line
120. Indium-111-diethylene-triaminepentaacetic acid-octreotide is delivered in vivo to pancreatic, tumor cell, renal, and hepatocyte lysosomes
121. 3]-octreotide, a promising somatostatin analogue for radionuclide therapy
122. 3]-octreotide by somatostatin receptor-positive cells in vitro and in vivo: Implications for somatostatin-targeted radioguided surgery
123. 3]octreotide: Peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy
124. New somatostatin analogues for radio-therapy of somatostatin receptor expressing tumors
125. 1]-octreotide
126. Yttrium-90-labelled somato-statin analogue for cancer treatment
127. Response to treatment with yttrium-90-DOTA-lanreotide of a patient with metastatic gastrinoma
128. Indium-111-DOTA-lanreotide: Biodistribution, safety and radiation absorbed dose in tumor patients
129. A selective analog for the somatostatin sst1-receptor subtype expressed by human tumors
130. Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry
131. Non-peptidal peptidomimetics with a β-D-glucose scaffolding. A partial somatostatin agonist bearing a close structural relationship to a potent, selective substance P agonist
132. De novo design and synthesis of somatostatin non-peptide pepti-domimetics utilizing β-D-glucose as a novel scaffolding
133. Design, synthesis and binding affinities of novel non-peptide mimics of somatostatin/sandostatin
134. Potent, orally bioavailable somatostatin agonists: Good absorption achieved by urea backbone cyclization
135. Novel somatostatin analogs for the treatment of acromegaly and cancer exhibit improved in vivo stability and distribution
136. Targeted approaches to cancer therapy
137. Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors
138. Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin
139. Cytotoxic analog of somatostatin containing methotrexate inhibits growth of MIA PaCa-2 human pancreatic cancer xenografts in nude mice
140. Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analog AN-238
141. Molecular biology and gene therapy in gastroenterology and hepatology
142. Gene therapy for cancer: What have we done where are we going?
143. Recent advances and perspective insights of gene therapy
144. Gene therapy: Different strategies for different applications
145. Gene therapy of cancer
146. Gene therapy for pancreatic carcinoma: Local and distant antitumor effects after somatostatin receptor sst2 gene transfer
147. sst2 somatostatin receptor expression reverses tumorigenicity of human pancreatic cancer cells
148. Genetic induction of antigens and receptors as targets for cancer radiotherapy
149. Somatostatin analogs in cancer management